Fig. 4
MSCs treated with poly(I:C) or LPS generate distinct immunomodulatory effects in an EAE model. Data show EAE clinical signs according to the different treatments of MSCs (either pretreated or not with TLR3 and TLR4 ligands). EAE was induced in C57BL/6 mice (n = 10/group) by subcutaneous immunization with 50 μg of MOG35–55 peptide, as described in Methods. MSC controls and MSCs pretreated with poly(I:C) or LPS were injected i.p. at day 4 (2 × 106/mouse) as described in Methods. (a) Scores were measured daily at the same time for 27 days and given a value of 0–5 according to loss of mobility in the lower and upper extremities. (b) The sum of the scores from day 10 to the end of the experiment was pooled by treatment group. Poly(I:C)-pretreated MSCs show a significantly lower cumulative score than that of EAE control mice. (c) Body weight loss (%), measured daily and clustered by treatment. A Wilcoxon rank test was used for comparisons with the untreated MSCs. *EAE + MSCsPoly compared with EAE and **EAE + MSCsLPS compared with EAE + MSCs with the matched pairs test, p < 0.001. MSCsPoly MSCs pretreated with poly(I:C) for 1 hour, MSCsLPS MSCs pretreated with LPS for 1 hour